Publié il y a 5 ans
OnDosis 01 prototype
This is the current prototype which has been tested in Human factor studies
21
1
OnDosis proprietary technology integrates oral prescription medicine with intelligent dosing in a handheld digital device. It is a prescribed regimen delivering flexible and individualized dosing of oral medicines formulated as small granules or micro-units. We are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.
The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often do not provide a good fit for the patient or treatment goal. OnDosis devices provide:
• Individualised - flexibility to accurately dose titrate medicine; ability to add personalised ID
• Intuitive - Use of pellets help patients with trouble swallowing pills; simple to use
• Connected – being digital the OnDosis device can link to smart health technology (e.g. wearables), an companion application supporting compliance and self-monitoring and creates scope to improve treatment outcomes
Publié il y a 5 ans
This is the current prototype which has been tested in Human factor studies
Publié il y a 5 ans
Grünenthal and OnDosis team up for individualised dosing of oral drugs in pain management to increase patient safety
Life science startup OnDosis signs its first global development and licensing agreement for their innovative technology. Grünenthal expands its portfolio with an innovative technology for individualised dosing.
Il n'y a pas encore d'organisations dans le réseau.